Adjuvant concurrent chemoradiation therapy in patients with microscopic residual tumor after curative resection for extrahepatic cholangiocarcinoma
We investigated the role of adjuvant concurrent chemoradiation therapy (CCRT) in patients with a microscopically positive resection margin (R1) after curative resection for extrahepatic cholangiocarcinoma (EHCC).
A total of 84 patients treated with curative resection for EHCC were included. Fifty-two patients with negative resection margins did not receive any adjuvant treatments (R0 + S group). The remaining 32 patients with microscopically positive resection margins received either adjuvant CCRT (R1 + CCRT group, n = 19) or adjuvant radiation therapy (RT) alone (R1 + RT group, n = 13).
During the median follow-up period of 26 months, the 2-year locoregional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival rates (OS) were: 81.8, 62.6, and 61.5% for R0 + S group; 71.8, 57.8, and 57.9% for R1 + CCRT group; and 16.8, 9.6, and 15.4% for R1 + RT group, respectively. Multivariate analysis revealed that the R1 + CCRT group did not show any significant difference in survival rates compared with the R0 + S group. The R1 + RT group had lower LRRFS [hazard ratio (HR) 3.008; p = 0.044], DFS (HR 2.364; p = 0.022), and OS (HR 2.417; p = 0.011) when compared with the R0 + S and R1 + CCRT group.
A lack of significant survival difference between R0 + S group and R1 + CCRT group suggests that adjuvant CCRT ameliorates the negative effect of microscopic positive resection margin. In contrast, adjuvant RT alone is appeared to be inadequate for controlling microscopically residual tumor.
KeywordsExtrahepatic cholangiocarcinoma Concurrent chemoradiation therapy Positive surgical margin Survival
Compliance with ethical standards
Conflict of interest
The authors declared that they have no conflicts of interest.
For this type of study, formal consent is not required.
Research involving human participants and/or animals
This article does not contain any studies with human participants and/or animals performed by any of authors.
- 1.Jarnagin WR, Ruo L, Little SA, Klimstra D, D’Angelica M, DeMatteo RP, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98(8):1689–700. https://doi.org/10.1002/cncr.11699.CrossRefPubMedGoogle Scholar
- 6.Ribero D, Amisano M, Lo Tesoriere R, Rosso S, Ferrero A, Capussotti L. Additional resection of an intraoperative margin-positive proximal bile duct improves survival in patients with hilar cholangiocarcinoma. Ann Surg. 2011;254(5):776–81. https://doi.org/10.1097/SLA.0b013e3182368f85 (discussion 81-3).CrossRefPubMedGoogle Scholar
- 7.Groot Koerkamp B, Wiggers JK, Allen PJ, Besselink MG, Blumgart LH, Busch OR, et al. Recurrence rate and pattern of perihilar cholangiocarcinoma after curative intent resection. J Am Coll Surg. 2015;221(6):1041–9. https://doi.org/10.1016/j.jamcollsurg.2015.09.005.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.van Gulik TM, Kloek JJ, Ruys AT, Busch OR, van Tienhoven GJ, Lameris JS, et al. Multidisciplinary management of hilar cholangiocarcinoma (Klatskin tumor): extended resection is associated with improved survival. Eur J Surg Oncol. 2011;37(1):65–71. https://doi.org/10.1016/j.ejso.2010.11.008.CrossRefPubMedGoogle Scholar
- 12.Oh D, Lim DH, Heo JS, Choi SH, Choi DW, Ahn YC, et al. The role of adjuvant radiotherapy in microscopic tumor control after extrahepatic bile duct cancer surgery. Am J Clin Oncol. 2007;30(1):21–5. https://doi.org/10.1097/01.coc.0000245467.97180.78.CrossRefPubMedGoogle Scholar
- 15.Borghero Y, Crane CH, Szklaruk J, Oyarzo M, Curley S, Pisters PW, et al. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol. 2008;15(11):3147–56. https://doi.org/10.1245/s10434-008-9998-7.CrossRefPubMedGoogle Scholar
- 18.Kim MY, Kim JH, Kim Y, Byun SJ. Postoperative radiotherapy appeared to improve the disease free survival rate of patients with extrahepatic bile duct cancer at high risk of loco-regional recurrence. Radiat Oncol J. 2016;34(4):297–304. https://doi.org/10.3857/roj.2016.01879.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Committee AJC. AJCC cancer staging manual. Chicago: AJCC; 2010.Google Scholar
- 21.Nakano K, Chijiiwa K, Toyonaga T, Ueda J, Takamatsu Y, Kimura M, et al. Combination therapy of resection and intraoperative radiation for patients with carcinomas of extrahepatic bile duct and ampulla of Vater: prognostic advantage over resection alone? Hepatogastroenterology. 2003;50(52):928–33.PubMedGoogle Scholar
- 23.Lim KH, Oh DY, Chie EK, Jang JY, Im SA, Kim TY, et al. Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study. BMC Cancer. 2009;9:345. https://doi.org/10.1186/1471-2407-9-345.CrossRefPubMedPubMedCentralGoogle Scholar